Latest Strategic Growth News

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Felix Gold is advancing its Treasure Creek Project in Alaska, aiming for the first domestic antimony concentrate production in over 30 years by late 2025 or early 2026, supported by strong government engagement and solid finances.

Grand Gulf Energy has secured an exclusive option for a major offshore Namibia oil block with over a billion barrels prospective resource and signed a strategic MoU to jointly explore helium and potash in Utah’s Paradox Basin.

RocketDNA reported steady revenue for the June 2025 quarter while significantly expanding its autonomous drone services across Australia, Africa, and Papua New Guinea. New contracts and operational milestones underscore its growing footprint in mining and government sectors.

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

Holista Colltech reported steady customer receipts and a 38% surge in dietary supplement sales for 2QFY25, while progressing its high-value nano-collagen business and refreshing its leadership team.

Greatland Resources has completed a landmark FY25, integrating Telfer and Havieron operations, producing nearly 200,000 ounces of gold, and raising $490 million in a successful ASX IPO. The company sets ambitious FY26 targets focused on extending Telfer’s mine life through its largest drilling program ever.

Vault Minerals delivered a robust June quarter with 98,459 ounces of gold produced and a significant cash flow boost, while advancing major upgrades at its King of the Hills operation.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.

Zenith Minerals reports a landmark quarter with a 41% increase in gold resources at Dulcie Far North, a strategic land acquisition, and a successful A$3.5 million entitlement offer to accelerate exploration.

Mount Burgess Mining NL has secured agreements to extinguish nearly $4.7 million in legacy debt, converting a small portion into equity and options, positioning the company for renewed growth.